Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2025Frontiers in OncologyOpen Access

Editorial: Refractory and relapsed hemophagocytic lymphohistiocytosis in pediatric population: targeted therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMădălina BotaSAS ̧ ener Akyol

Discussion

Loading...

Member takes

Overview

Editorial highlights variability in hemophagocytic lymphohistiocytosis etiology and suggests targeted therapies may improve outcomes.

Key Points

  • Targeted therapies for refractory hemophagocytic lymphohistiocytosis have shown promise in pediatric cases, addressing underlying immune dysregulation.
  • Recent cohort analysis of 52 patients indicated high mortality rates up to 30.8%, emphasizing the urgent need for individualized treatment strategies.
  • Traditional treatments include immunosuppression and HSCT, but refractory cases may require novel therapies like JAK–STAT inhibitors.
  • Complex diagnoses in pediatric populations highlight the necessity for multidisciplinary approaches to achieve optimal treatment outcomes.

Cite This Study

Bota et al. (2025) studied this question.

synapsesocial.com/papers/68d43285713b0b5dfea71bbfhttps://doi.org/10.3389/fonc.2025.1691878
View Full Paper
Ask AI
Bookmark
Share